BR9910947A - Estabilização de composições que contêm inibidores de ace utilizando óxido de magnésio - Google Patents

Estabilização de composições que contêm inibidores de ace utilizando óxido de magnésio

Info

Publication number
BR9910947A
BR9910947A BR9910947-6A BR9910947A BR9910947A BR 9910947 A BR9910947 A BR 9910947A BR 9910947 A BR9910947 A BR 9910947A BR 9910947 A BR9910947 A BR 9910947A
Authority
BR
Brazil
Prior art keywords
magnesium oxide
compositions containing
stabilization
ace
inhibitor
Prior art date
Application number
BR9910947-6A
Other languages
English (en)
Inventor
Jane Ellen Daniel
Michael Ray Harris
Gerard Clifford Hokanson
Jay Weiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9910947(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9910947A publication Critical patent/BR9910947A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção:<B>''ESTABILIZAçãO DE COMPOSIçõES QUE CONTêM INIBIDORES DE ACE UTILIZANDO óXIDO DE MAGNéSIO"<D>. A presente invenção está direcionada às composições contendo inibidor de ACE estalilizadas pela presença de óxido de magnésio. Preferencialmente, o inibidor de ACE, quinapril, é protegido de certas formas de degradação quando preparado em uma composição farmacêutica que consiste essencialmente de óxido de magnésio como o agente estabilizador. A presença de óxido de magnésio também se presta a condições favoráveis de processamento durante a fabricação de composições contendo inibidor de ACE, especialmente o processamento por granulação úmida.
BR9910947-6A 1998-06-05 1999-05-10 Estabilização de composições que contêm inibidores de ace utilizando óxido de magnésio BR9910947A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05
PCT/US1999/010189 WO1999062560A1 (en) 1998-06-05 1999-05-10 Stabilization of compositions containing ace inhibitors using magnesium oxide

Publications (1)

Publication Number Publication Date
BR9910947A true BR9910947A (pt) 2001-03-06

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910947-6A BR9910947A (pt) 1998-06-05 1999-05-10 Estabilização de composições que contêm inibidores de ace utilizando óxido de magnésio

Country Status (32)

Country Link
US (3) US6417196B1 (pt)
EP (1) EP1083931B1 (pt)
JP (1) JP3727848B2 (pt)
KR (1) KR20010052557A (pt)
CN (1) CN1144598C (pt)
AR (1) AR019150A1 (pt)
AT (1) ATE295184T1 (pt)
AU (1) AU755616B2 (pt)
BR (1) BR9910947A (pt)
CA (1) CA2330581A1 (pt)
CO (1) CO5011043A1 (pt)
DE (1) DE69925269T2 (pt)
ES (1) ES2242398T3 (pt)
GT (1) GT199900079A (pt)
HK (1) HK1038879B (pt)
HN (1) HN1999000088A (pt)
HU (1) HUP0102260A3 (pt)
ID (1) ID27398A (pt)
IL (1) IL139590A0 (pt)
IS (1) IS2270B (pt)
MY (1) MY119667A (pt)
NO (1) NO20006148D0 (pt)
NZ (1) NZ508544A (pt)
PA (1) PA8475001A1 (pt)
PE (1) PE20000543A1 (pt)
PL (1) PL344586A1 (pt)
SV (1) SV1999000072A (pt)
TR (1) TR200003600T2 (pt)
TW (1) TW565455B (pt)
UY (1) UY25546A1 (pt)
WO (1) WO1999062560A1 (pt)
ZA (1) ZA200006537B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL344586A1 (en) * 1998-06-05 2001-11-05 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
DK1300160T3 (da) * 2000-05-24 2014-03-24 Otsuka Pharma Co Ltd Fremgangsmåde til stabilisering af en sammensætning
DE60312857T2 (de) * 2002-01-15 2008-01-17 Actavis Group Hf. Formulierungen von quinapril und verwandte ace-hemmer
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
DK1635792T3 (da) * 2003-06-26 2009-06-15 Teva Pharma Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
JP4922762B2 (ja) * 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
CA2647705A1 (en) * 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
EP2034966A1 (en) * 2006-06-30 2009-03-18 Alphapharm Pty Ltd. A stabilised composition comprising ace inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) 1967-05-16 Method of preparing magnesia
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4830853A (en) 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
PL344586A1 (en) * 1998-06-05 2001-11-05 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
US6417196B1 (en) 2002-07-09
HK1038879B (zh) 2004-10-08
CO5011043A1 (es) 2001-02-28
DE69925269D1 (de) 2005-06-16
TR200003600T2 (tr) 2001-04-20
JP3727848B2 (ja) 2005-12-21
PA8475001A1 (es) 2000-09-29
WO1999062560A1 (en) 1999-12-09
UY25546A1 (es) 1999-09-27
HK1038879A1 (en) 2002-04-04
JP2002516881A (ja) 2002-06-11
CA2330581A1 (en) 1999-12-09
HUP0102260A3 (en) 2002-12-28
ID27398A (id) 2001-04-05
ES2242398T3 (es) 2005-11-01
ATE295184T1 (de) 2005-05-15
AR019150A1 (es) 2001-12-26
IS2270B (is) 2007-07-15
US7015232B2 (en) 2006-03-21
EP1083931B1 (en) 2005-05-11
AU3979399A (en) 1999-12-20
TW565455B (en) 2003-12-11
HN1999000088A (es) 2000-02-10
DE69925269T2 (de) 2006-02-23
US20060106057A1 (en) 2006-05-18
NO20006148L (no) 2000-12-04
CN1304322A (zh) 2001-07-18
US20020161020A1 (en) 2002-10-31
NZ508544A (en) 2002-10-25
PL344586A1 (en) 2001-11-05
MY119667A (en) 2005-06-30
NO20006148D0 (no) 2000-12-04
CN1144598C (zh) 2004-04-07
HUP0102260A2 (hu) 2002-03-28
EP1083931A1 (en) 2001-03-21
KR20010052557A (ko) 2001-06-25
AU755616B2 (en) 2002-12-19
SV1999000072A (es) 2000-05-04
GT199900079A (es) 2000-11-25
IS5712A (is) 2000-11-10
ZA200006537B (en) 2001-11-12
PE20000543A1 (es) 2000-08-10
IL139590A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
BR9910947A (pt) Estabilização de composições que contêm inibidores de ace utilizando óxido de magnésio
ES2292868T3 (es) Agente para la odorificacion de un gas.
BR0213546A (pt) Composições ácidas de sanitização e limpeza contendo ácidos carboxìlicos protonados
ATE421248T1 (de) Antiseptische zusammensetzungen und verfahren
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
HU9601449D0 (en) Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
BR9810869A (pt) Inibição de polimerização de acrilatos usando misturas de nitróxidos
TW200716184A (en) Inhibitor for parakeratosis, pore reducing agent or skin roughening preventing or ameliorating agent and composition for skin care preparation
CO5650219A2 (es) Pelicula antiplaca consumible refrescante del aliento
AR027533A1 (es) Derivados de acido malonico, procesos para su preparacion, su uso y composiciones farmaceuticas que los contienen
BRPI0413964A (pt) ácido derivado do ácido carboxìlico quinolona, sua composição e agente antibacterial
WO2010039654A3 (en) Topical treatment of skin infection
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
HUE009867T2 (pt)
GB0105837D0 (en) Pharmaceutical compositions including alginates
BR0104656A (pt) Composição polimérica normalmente suceptìvel a decomposição induzida pelo calor, e, composição estabilizadora
BR0110780A (pt) Formulação contendo fenolatos tendo um ponto de congelamento baixo
DE60121459D1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs
BR0102940A (pt) Agente para o tratamento de doença de parkinson compreendendo um agente de melhora da função de astrócitos como ingrediente ativo
BR0113175A (pt) Derivados da quinolina como agentes antiinflamação
GEP19981355B (en) Method for Selectively Obtaining 3/2 Hydrate of 7- S - amono- S -azaspiro-2,4-heptan-5-yl-8-chloro-6- fluoro-1-(1R,2S)-2-fluorocyclopropyl - 4-oxo-1,4-dihydroquinoline-3 Carboxyl Acid its Anhydrous Form and Pharmaceutical Composition Comprising Anhydrous Form
ECSP992981A (es) Composiciones estabilizadas
DE60219462D1 (de) Verdickte wässrige zusammensetzungen
DE60213361D1 (de) Flüssige antimikrobielle zusammensetzungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.